Omnicell, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied figures compare full fiscal years, not standalone fourth-quarter results.
Business context
Omnicell sells medication-management automation, software, consumables, and related services to healthcare providers and pharmacies. It reports as one operating segment and generated approximately 90% of 2022 revenue in the United States. Its strategy emphasizes connected automation and subscription-based “Advanced Services,” including central pharmacy, IV compounding, specialty pharmacy, 340B, inventory optimization, and patient-engagement offerings.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Total revenue | $1,295.9 million | $1,132.0 million |
| Product revenue | $903.2 million | $812.5 million |
| Services and other revenue | $392.7 million | $319.5 million |
| Gross profit / margin | $589.0 million / 45% | $554.7 million / 49% |
| Operating income (loss) | $(2.3) million | $89.5 million |
| Net income | $5.6 million | $77.8 million |
| Diluted earnings per share | $0.12 | $1.62 |
| Cash from operating activities | $77.8 million | $231.8 million |
- Revenue increased 14%. Advanced Services revenue rose to $186.0 million from $112.5 million; connected devices, software licenses, and other revenue was $827.9 million, versus $739.1 million.
- Bookings fell 13% to $1.054 billion, primarily on lower connected-device demand, partly offset by Advanced Services demand and acquisitions. Total backlog was $1.215 billion, down from $1.254 billion; Advanced Services backlog increased to $418.5 million from $277.1 million.
- Gross margin declined four percentage points. Management attributed pressure to service investments and mix, lower 340B revenue, inflation-related inventory costs, and higher employee and travel expenses.
- Cash and cash equivalents were $330.4 million at year-end, compared with $349.1 million. Working capital was $453.4 million; the current ratio was 2.1, versus 0.9 in 2021. The prior-year ratio was affected by classifying the convertible notes as current.
- Convertible notes had $575.0 million principal and a $566.6 million carrying value at year-end; they bear 0.25% interest and mature in September 2025. There were no borrowings under the $500 million revolving facility, and the company reported covenant compliance.
Material changes, outlook, and risks
- Operating expenses rose 27% to $591.3 million, exceeding gross-profit growth. SG&A included $9.4 million of lease-asset impairment and abandonment charges and $2.0 million of net ransomware-related expense. Restructuring charges totaled $22.8 million for 2022.
- Management announced workforce reductions affecting approximately 350 employees in November 2022 and an additional approximately 60 employees plus real-estate reductions in February 2023. It estimated about $13 million of additional nonrecurring restructuring charges in 2023; expected savings are not assured.
- A May 2022 ransomware incident delayed invoicing and cash collections and disrupted some customer implementations. The company reported restoring substantially all critical systems and completing substantially all delayed implementations by year-end. It incurred $13.6 million of incident costs and expected $11.1 million in insurance recoveries.
- Management said cash, expected operating cash flow, and available credit should meet anticipated needs for at least the next twelve months. The filing does not provide a clear numerical revenue or earnings guidance target.
- Principal risks include customer capital-spending and installation delays, subscription adoption and renewal, supply constraints and inflation (especially semiconductors), competition, execution and integration of acquisitions, cybersecurity and privacy, healthcare regulation and 340B program changes, and debt obligations. 340B-related revenue declined amid lower provider utilization following drug-manufacturer actions.
- A class action alleging violations of Illinois biometric privacy law had a settlement preliminarily approved; final approval was scheduled for April 6, 2023. The company reported no material accrual, stating a material loss was reasonably possible but not probable and the estimated range was not material.
Important facts for investors to verify
- Whether bookings, product backlog, and installation timing recover, and how much backlog converts to revenue on schedule.
- Whether Advanced Services growth translates into improved margins and cash generation, including customer renewal and contract economics.
- Drivers of the sharp year-over-year declines in operating income, net income, and operating cash flow, and the outlook for margins after restructuring.
- The timing and cash impact of the $575 million notes due in 2025, including any conversion, refinancing, or liquidity implications.
- Final BIPA settlement terms and costs, actual ransomware insurance recoveries, and any continuing cybersecurity or customer impact.
- Whether supply-chain costs, 340B developments, and the 2023 workforce and facility reductions affect demand, delivery capacity, and expected savings.